Oxbow Advisors LLC Sells 3,563 Shares of GSK plc (NYSE:GSK)

Oxbow Advisors LLC reduced its position in shares of GSK plc (NYSE:GSK) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 137,172 shares of the pharmaceutical company’s stock after selling 3,563 shares during the period. Oxbow Advisors LLC’s holdings in GSK were worth $4,639,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. FMR LLC boosted its holdings in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares during the last quarter. Primecap Management Co. CA boosted its holdings in GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after acquiring an additional 342,365 shares during the last quarter. Provident Trust Co. boosted its holdings in GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after acquiring an additional 66,765 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC boosted its holdings in GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after acquiring an additional 833,080 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

GSK stock opened at $36.62 on Friday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The stock’s 50 day moving average price is $34.61 and its two-hundred day moving average price is $37.36. The stock has a market capitalization of $75.91 billion, a price-to-earnings ratio of 23.03, a PEG ratio of 1.11 and a beta of 0.64.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, equities analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.29%. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio is presently 93.08%.

Wall Street Analyst Weigh In

GSK has been the topic of several analyst reports. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and reduced their target price for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.